{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:29:36Z","timestamp":1793276976963,"version":"4.5.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There are an estimated 257 million persons living with chronic hepatitis B for whom there are multiple potential applications of long-acting antiviral compounds. Current efforts include both injection and implant approaches to formulating derivates of existing anti-HBV compounds such as tenofovir or entecavir. Substantial progress has already occurred especially as aligned with the development of long-acting tenofovir-based medications with dual activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Nonetheless, substantial challenges will need to be overcome before these agents are available.<\/jats:p>","DOI":"10.1093\/cid\/ciac718","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T21:45:00Z","timestamp":1669067100000},"page":"S517-S524","source":"Crossref","is-referenced-by-count":16,"title":["Long-Acting Treatments for Hepatitis B"],"prefix":"10.1093","volume":"75","author":[{"given":"David L","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, The Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J","family":"Kiser","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science , Monrovia, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"2022112121391061100_ciac718-B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022112121391061100_ciac718-B2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022112121391061100_ciac718-B3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2022112121391061100_ciac718-B4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"2022112121391061100_ciac718-B5","doi-asserted-by":"crossref","first-page":"ofaa367","DOI":"10.1093\/ofid\/ofaa367","article-title":"Acute hepatitis B infection after a switch to long-acting cabotegravir and rilpivirine","volume":"7","author":"Pintado","year":"2020","journal-title":"Open Forum Infects Dis"},{"key":"2022112121391061100_ciac718-B6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022112121391061100_ciac718-B7","author":"WHO"},{"key":"2022112121391061100_ciac718-B8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent perinatal transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"New Engl J Med"},{"key":"2022112121391061100_ciac718-B9","doi-asserted-by":"crossref","first-page":"e1600","DOI":"10.1016\/S2214-109X(21)00304-1","article-title":"Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study","volume":"9","author":"Thompson","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2022112121391061100_ciac718-B10","volume-title":"Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015"},{"key":"2022112121391061100_ciac718-B11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J Control Release"},{"key":"2022112121391061100_ciac718-B12","doi-asserted-by":"crossref","first-page":"603242","DOI":"10.3389\/fphar.2020.603242","article-title":"Bictegravir plus tenofovir alafenamide nanoformulation as a long-acting pre-exposure prophylaxis regimen: application of modeling to design non-human primate pharmacokinetic experiments","volume":"11","author":"Perazzolo","year":"2020","journal-title":"Front Pharmacol"},{"key":"2022112121391061100_ciac718-B13","doi-asserted-by":"crossref","first-page":"e02320","DOI":"10.1128\/AAC.02320-20","article-title":"A concept evaluation study of a new combination bictegravir plus tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 preexposure prophylaxis","volume":"65","author":"Mandal","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112121391061100_ciac718-B14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"key":"2022112121391061100_ciac718-B15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022112121391061100_ciac718-B16","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.xphs.2018.03.005","article-title":"Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5\u00a0weeks after a single subcutaneous injection","volume":"107","author":"McConnachie","year":"2018","journal-title":"J Pharm Sci"},{"key":"2022112121391061100_ciac718-B17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.nano.2013.05.003","article-title":"Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections","volume":"9","author":"Puligujja","year":"2013","journal-title":"Nanomedicine"},{"key":"2022112121391061100_ciac718-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25690-5","article-title":"Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles","volume":"12","author":"Cobb","year":"2021","journal-title":"Nat Commun"},{"key":"2022112121391061100_ciac718-B19","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022112121391061100_ciac718-B20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/aid.2021.0028","article-title":"Tenofovir alafenamide for HIV prevention: review of the proceedings from the Gates Foundation long-acting TAF product development meeting","volume":"37","author":"Romano","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022112121391061100_ciac718-B21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J Control Release"},{"key":"2022112121391061100_ciac718-B22","doi-asserted-by":"crossref","first-page":"2000163","DOI":"10.1002\/adtp.202000163","article-title":"Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates","volume":"4","author":"Pons-Faudoa","year":"2021","journal-title":"Adv Ther"},{"key":"2022112121391061100_ciac718-B23","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm Res"},{"key":"2022112121391061100_ciac718-B24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"},{"key":"2022112121391061100_ciac718-B25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/pharmaceutics12111057","article-title":"Performance and stability of tenofovir alafenamide formulations within subcutaneous biodegradable implants for HIV pre-exposure prophylaxis (PrEP)","volume":"12","author":"Li","year":"2020","journal-title":"Pharmaceutics"},{"key":"2022112121391061100_ciac718-B26","doi-asserted-by":"crossref","first-page":"e01893-19","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112121391061100_ciac718-B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11095-020-2777-2","article-title":"Design of a drug-eluting subcutaneous implant of the antiretroviral tenofovir alafenamide fumarate","volume":"37","author":"Simpson","year":"2020","journal-title":"Pharmaceut Res"},{"key":"2022112121391061100_ciac718-B28","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112121391061100_ciac718-B29","doi-asserted-by":"crossref","first-page":"569373","DOI":"10.3389\/fphar.2020.569373","article-title":"Multispecies evaluation of a long-acting tenofovir alafenamide subdermal implant for HIV prophylaxis","volume":"11","author":"Gunawardana","year":"2020","journal-title":"Front Pharmacol"},{"key":"2022112121391061100_ciac718-B30","first-page":"e052880","article-title":"CAPRISA 018: a phase I\/II trial to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide sub-dermal implant for HIV prevention in women","volume":"6","author":"Gengiah","year":"2021","journal-title":"BMJ Open"},{"key":"2022112121391061100_ciac718-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-11020-2","article-title":"Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis","volume":"12","author":"Gunawardana","year":"2022","journal-title":"Sci Rep"},{"key":"2022112121391061100_ciac718-B32","year":"2005"},{"key":"2022112121391061100_ciac718-B33","doi-asserted-by":"crossref","first-page":"104958","DOI":"10.1016\/j.ejps.2019.104958","article-title":"Exploration of long-acting implant formulations of hepatitis B drug entecavir","volume":"136","author":"Henry","year":"2019","journal-title":"Eur J Pharmaceut Sci"},{"key":"2022112121391061100_ciac718-B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2019.01.052","article-title":"Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: preparation and in vitro and in vivo evaluation","volume":"560","author":"Zhang","year":"2019","journal-title":"Int J Pharm"},{"key":"2022112121391061100_ciac718-B35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2018.06.024","article-title":"Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery","volume":"130","author":"Ho","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"2022112121391061100_ciac718-B36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jhep.2020.12.006","article-title":"Identification of a novel long-acting 4\u2032-modified nucleoside reverse transcriptase inhibitor against HBV","volume":"74","author":"Higashi-Kuwata","year":"2021","journal-title":"J Hepatol"},{"key":"2022112121391061100_ciac718-B37","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/jac\/dkz187","article-title":"Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate","volume":"74","author":"Brooks","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022112121391061100_ciac718-B38","doi-asserted-by":"crossref","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"key":"2022112121391061100_ciac718-B39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1201","article-title":"Pharmacologic-based methods of adherence assessment in HIV prevention","volume":"104","author":"Brooks","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2022112121391061100_ciac718-B40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study","volume":"84","author":"Yager","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022112121391061100_ciac718-B41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jiz144","article-title":"Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV","volume":"220","author":"Morrow","year":"2019","journal-title":"J Infect Dis"},{"key":"2022112121391061100_ciac718-B42","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022112121391061100_ciac718-B43","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2016.05.016","article-title":"Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naive patients with chronic hepatitis B","volume":"48","author":"Boglione","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2022112121391061100_ciac718-B44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpba.2015.05.016","article-title":"UPLC-MS\/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients","volume":"114","author":"De Nicol\u00f2","year":"2015","journal-title":"J Pharm Biomed Anal"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_4\/S517\/47170388\/ciac718.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_4\/S517\/47170388\/ciac718.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T21:45:35Z","timestamp":1669067135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_4\/S517\/6835724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":44,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2022,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac718","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,11,21]]}}}